Table 2.
Prevalence of high- and low-risk HPV types stratified by age groups and cytological results.
| HPV 16 | HPV 18 | HPV 51 | Other than HPV 16 and 51 HR types | Nearest non-vaccine types (31, 33, 45, 52, 58) | HR types | LR types | Any HPV type | Mono-infection | Co-infection with HR and/or LR types | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | 95% CIs | n (%) | 95% CIs | n (%) | 95% CIs | n (%) | 95% CIs | n (%) | 95% CIs | n (%) | 95% CIs | n (%) | 95% CIs | n (%) | 95% CIs | n (%) | 95% CIs | n (%) | 95% CIs | ||
| Age | 15-24 | 11 (21.2) | 10.1-32.3 |
5 (9.6) |
1.6-17.6 | 7 (13.5) | 4.2-22.8 | 15 (28.9) | 16.6-41.2 | 7 (31.8) | 12.3-51.3 | 28 (53.9) | 40.4-67.5 | 10 (19.2) | 8.3-29.7 |
28 (53.9) |
40.4-67.5 | 12 (23.1) | 11.7-34.6 | 16 (30.8) | 18.3-43.4 |
| 25-34 | 19 (21.8) | 13.1-30.5 |
1 (1.2) |
-1.1-3.5 | 11 (12.6) | 5.6-19.6 | 16 (18.4) | 10.3-26.5 | 8 (36.4) | 16.3-56.5 |
31 (35.6) |
25.5-45.7 | 10 (11.5) | 4.4-17.6 |
36 (41.4) |
31.1-51.8 | 20 (23.0) | 14.2-31.8 | 16 (18.4) | 10.3-26.5 | |
| 35-44 | 25 (22.3) | 14.6-30.0 |
0 (0.0) |
0.0-0.0 | 20 (17.9) | 10.8-25.0 | 7 (6.3) | 1.8-10.8 | 5 (22.7) | 5.2-40.2 | 35 (31.3) | 22.7-39.9 | 5 (4.5) | 0.6-8.2 |
36 (32.1) |
23.5-40.8 | 16 (14.3) | 10.8-25.0 | 20 (17.9) | 10.8-25.0 | |
| 45-54 | 8 (11.3) | 4.0-18.6 |
0 (0.0) |
0.0-0.0 | 6 (8.3) | 2.0-15.0 | 7 (9.7) | 2.9-16.5 | 2 (9.1) | -2.9-21.1 | 14 (19.4) | 10.3-28.5 | 3 (4.2) | 0.2-10.8 |
16 (22.2) |
12.6-31.8 | 9 (12.5) | 2.9-16.5 | 7 (9.7) | 2.9-16.5 | |
| PAP-test | Normal | 48 (19.9) | 4.9-49.0 |
3 (1.2) |
-0.2-2.6 | 32 (13.2) | 8.9-17.5 |
21 (8.7) |
5.2-12.3 | 13 (5.4) | 2.6-8.3 | 84 (34.7) | 28.7-40.7 | 18 (7.4) | 4.2-10.8 | 78 (32.2) | 26.3-38.1 | 42 (17.4) | 12.6-22.2 | 41 (16.9) | 12.2-21.6 |
| ASCUS | 4 (12.5) | 1.0-24.0 |
2 (6.3) |
-2.1-14.7 | 2 (6.3) | -2.1-14.7 | 9 (28.1) | 12.4-43.6 | 4 (12.5) | 1.0-24.0 | 9 (28.1) | 12.5-43.7 | 5 (15.6) | 2.6-27.4 | 14 (43.8) | 26.6-61.0 | 5 (15.6) | 3.0-28.2 | 7 (21.9) | 7.6-36.2 | |
| LSIL | 6 (24.0) | 7.3-40.7 |
1 (4.0) |
-3.7-11.7 | 4 (16.0) | 1.6-30.4 | 4 (16.0) | 1.6-30.4 | 3 (12.0) | 0.7-24.7 | 9 (36.0) | 17.2-54.8 | 5 (20) | 4.3-35.7 | 13 (52.0) | 32.4-71.6 | 6 (24.0) | 7.3-40.7 | 7 (28.0) | 10.4-45.6 | |
| HSIL | 2 (50.0) | 1.0-99.0 |
0 (0.0) |
0.0-0.0 | 2 (50.0) | 1.0-99.0 | 1 (25.0) | -17.4-67.4 | 1 (25.0) | -17.4-67.4 |
3 (75.0) |
32.5-100.0 | 0 (0.0) | 0.0-0.0 | 4 (100.0) | 1-1 | 1 (25.0) | -17.4-67.4 | 2 (50.0) | 1.0-99.0 | |
| All screened sample | 63 (19.5) | 15.3-23.9 |
6 (1.9) |
0.4-3.4 | 44 (13.6) | 9.9-17.5 | 45 (13.9) | 10.2-17.8 | 22 (6.8) | -3.7-17.4 | 108 (33.4) | 28.3-38.5 | 28 (8.7) | 5.6-11.8 |
116 (35.9) |
30.7-41.1 | 57 (17.7) | 13.5-21.9 | 59 (18.3) | 13.8-22.2 | |
CIs: Confidence Intervals
ASCUS: Atypical Squamous Cells of Undetermined Significance
LSIL: Low-grade Squamous Intra-epithelial Lesion
HSIL: High-grade Squamous Intra-epithelial Lesion
HR: High-Risk genotype
LR: Low-Risk genotype